Wordt geladen...
Progress with palbociclib in breast cancer: latest evidence and clinical considerations
Deregulation of the cell cycle is a hallmark of cancer, and research on cell cycle control has allowed identification of potential targets for anticancer treatment. Palbociclib is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved, with their coregulatory part...
Bewaard in:
| Gepubliceerd in: | Ther Adv Med Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publications
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5298405/ https://ncbi.nlm.nih.gov/pubmed/28203301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016677961 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|